CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


RibavirinWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (7)


Name (Synonyms) Correlation
drug1371 Lopinavir/Ritonavir 400 mg/100 mg Wiki 0.71
drug770 Digital cardiac Counseling Wiki 0.71
drug3004 sofosbuvir Wiki 0.71
drug709 Daclatasvir Wiki 0.50
drug1220 Interferon Beta-1B Wiki 0.41
drug1372 Lopinavir/ritonavir Wiki 0.22
drug1822 Placebo Wiki 0.04

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D002318 Cardiovascular Diseases NIH 0.15
D007239 Infection NIH 0.04
D045169 Severe Acute Respiratory Syndrome NIH 0.04
D018352 Coronavirus Infections NIH 0.03

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0001626 Abnormality of the cardiovascular system HPO 0.15

There are 2 clinical trials

Clinical Trials


1 An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection

A combination of lopinavir/ ritonavir, ribavirin and interferon beta-1b will expedite the recovery, suppress the viral load, shorten hospitalisation and reduce mortality in patients with 2019-n-CoV infection compared with to lopinavir/ ritonavir

NCT04276688 Novel Coronavirus Infection Drug: Lopinavir/ritonavir Drug: Ribavirin Drug: Interferon Beta-1B
MeSH:Infection Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: Time to negative NPS 2019-n-CoV RT-PCR

Measure: Time to negative NPS

Time: Up to 1 month

Secondary Outcomes

Description: Time to negative saliva 2019-n-CoV RT-PCR

Measure: Time to negative saliva

Time: Up to 1 month

Description: Time to NEWS of 0

Measure: Time to clinical improvement

Time: Up to 1 month

Description: Length of hospitalisation

Measure: Hospitalisation

Time: Up to 1 month

Description: 30-day mortality

Measure: Mortality

Time: Up to 1 month

Description: Cytokine/ chemokine changes

Measure: Immune reaction

Time: up to 1 month

Description: Adverse events during treatment

Measure: Adverse events

Time: up to 1 month

Description: Time to negative NPS, saliva, urine and stool 2019-n-CoV RT-PCR

Measure: Time to negative all clinical specimens

Time: up to 1 month

2 Sofosbuvir With and Without Ribavirin in Treatment of COVID 19 Patients

Sofosbuvir with and without ribavirin in treatment of COVID 19 Egyptian patients

NCT04460443 COVID Drug: sofosbuvir Drug: Ribavirin Drug: Daclatasvir

Primary Outcomes

Description: The total number of patients with response to treatment

Measure: Number of patients with response to treatment

Time: 1 month


No related HPO nodes (Using clinical trials)